Thioridazine Enhances Cisplatin-Induced DNA Damage in Cisplatin-Resistant Human Lung Cancer Cells

Yuanyuan Luo*, Tinghe Yu, Xinya Li, and Guanhua Qian*

Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China

Correspondence should be addressed to Guanhua Qian; qianguanhua@cqmu.edu.cn

Received 7 December 2021; Revised 17 February 2022; Accepted 10 March 2022; Published 30 March 2022

Academic Editor: Xi Wei

Copyright © 2022 Yuanyuan Luo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Thioridazine was used to sensitize cisplatin against cisplatin-resistant human lung cancer cells. Cells received thioridazine, cisplatin, or both drugs (the combination). Thioridazine synergized cisplatin to increase percentages of dead and apoptotic cells. DNA damage was detected using the comet assays; the combination led to the highest alkaline- and neutral-comet percentages, demonstrating exacerbation of both single- and double-strand breaks. After thioridazine treatment, levels of glutathione, and BRCA2, RAD51, and ERCC1 proteins were decreased. These data manifested that thioridazine decreased the capacities of detoxification and DNA repair, thereby enhancing cisplatin-induced DNA damage in resistant cells.

1. Introduction

Lung cancer remains one of the most lethal malignancies worldwide, and cisplatin (DDP) is the first-line agent; however, the development of chemoresistance decreases the therapeutic responses and ultimately results in treatment failure [1–3]. Intracellular DDP is hydrated to generate the active forms, which induce DNA damage to cause apoptosis [3]. DDP resistance is multifactor, including drug influx and efflux, detoxification, DNA repair, and apoptosis malfunction [4–7]. Consequently, overcoming resistance is yet a challenge.

Thioridazine (THD) is commonly an antipsychotic drug. Recent data have demonstrated that THD can inhibit the proliferation of certain cancer cells (such as ovary, lung, uterine cervix, esophagus, melanoma, glioblastoma, and liver) [8–11]. THD binds to dopamine receptors on the cell membranes to activate biological reactions, i.e., THD can modulate the behavior of cells expressing dopamine receptors [12]. Our previous studies have indicated that THD can sensitize DDP against chemoresistant human lung cancer cells via enhancing apoptosis [10]. For cytotoxicity of DDP, DNA damage is the upstream event of apoptosis. However, how THD modulates DNA damage attributable to DDP has not been elucidated yet.

The aim of this study was to explore mechanisms of chemosensitization in resistant lung cancer cells from the perspective of DNA damage. Preliminary data indicated that THD enhanced DDP-induced DNA insults via modulating detoxification and DNA repair.

2. Materials and Methods

2.1. Cells.

Human lung cancer cell line A549 and the chemoresistant subline A549/DDP were cultured in RPMI-1640 medium (GIBCO) supplemented with 10% fetal bovine serum (Biol. Ind., Kibbutz Beit-Haemek, Israel), at 37°C and 5% CO₂. DDP (2.0 mg/mL; Qilu Pharm. Co. Ltd., Jinan, China) was added to the medium of A549/DDP to maintain the resistance phenotype. To avoid interferences of residual DDP, A549/DDP cells were transferred to DDP-free medium for 5 days before experiments [13, 14].

2.2. Cell Viability.

Cells (5000 cells/well) were seeded on a 96-well plate and then were treated with THD (0, 5, 10, 15, 20, 25, 30, 35, and 40 μM; Sigma-Aldrich, Darmstadt, Germany) or DDP (0, 5, 10, 20, 40, 80, 160, and 320 μM) for 24 h. Drugs were washed away, and then, cells were cultured...
in complete medium. Cell vitality was detected at 24 h (i.e., 48 h after administering drugs) using a CCK-8 assay (Dojindo Lab., Kumamoto, Japan), and the half-maximal inhibitory concentration (IC_{50}) was calculated.

Based on the cell survival percentages, 20 μM THD and 40 μM DDP were adopted in the combination regimen. Cells were subjected to THD and/or DDP for 24 h, and the viability was determined at 0, 24, and 48 h (i.e., 24, 48, and 72 h after administering drugs).

2.3. Detection of Apoptotic Cells. Apoptosis were determined using the Annexin V assay (Keygen Biotech., Nanjing, China) at 24 h after administering drugs. Apoptotic cells were the sum of early (V+/PI−) and late (V+/PI+) apoptotic cells.

2.4. Assessment of the Combination Effect. The combination index (CI) was calculated using percentages of dead cells (1-survival percentage), thereby determining the interaction between THD and DDP.

\[
CI = \frac{E_{A+B}}{(E_A + E_B - E_A \times E_B)}
\]

\(E_{A+B}\) was the effect of combination, and \(E_A\) or \(E_B\) was the effect of a single drug. A CI value of >1.15 indicated synergism, and 0.85–1.15 was addition [15].

2.5. Concentration of Glutathione (GSH). The intracellular levels of GSH and GSSG were determined at 24 h after administering drugs using a kit (Beyotime Biotechnol., Shanghai, China).

2.6. Measurement of Reactive Oxygen Species (ROS). Cells were treated as above and then incubated with 10 μM dichlorofluorescein diacetate (DCFH–DA) (Beyotime Biotechnol., Shanghai, China) in darkness at 37°C for 30 min. ROS was determined with fluorescent spectrophotometry. \(\lambda_{ex}\) was 488 nm, and \(\lambda_{em}\) was 525 nm [16].

2.7. DNA Damage Detected with Comet Assays. Comet assays were performed to detect DNA damage at 24 h after administering drugs. The alkaline assay detected both single-strand break (SSB) and double-strand break (DSB), and the neutral assay detected DSB. The percentage of comet-formed cells reflected the level of DNA damage [17].

2.8. Western Blot. Cells were harvested at 24 h after administering drugs. Proteins were extracted using the RIPA kit (Beyotime Biotechnol., Shanghai, China). Proteins (40 μg/well) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride membrane. Rabbit antibodies (Abcam, Cambridge, UK) against BRCA2 (polyclonal), RAD51 (monoclonal), ERCC1 (monoclonal), and β-actin (monoclonal) were used. Rat-anti-rabbit IgG antibody (Abcam, Cambridge, UK) was the secondary antibody. Proteins were visualized by an enhanced chemiluminescence kit (Pierce Biotechnol., Rockford, USA). β-actin was the reference to quantify the expression level of a target protein.

2.9. Statistical Analysis. The IBM SPSS 26.0 (IBM, USA) software was used for statistical analyses. Analysis of variance (ANOVA) was adopted and the least significant difference (LSD) was used for multiple comparisons. The critical value was set \(p < 0.05\).

3. Results

3.1. THD Synergized DDP against Resistant Cells. Either DDP or THD dose-dependently deactivated A549 or A549/DDP cells (\(p < 0.001\)) (Figures 1(a) and 1(b)). Both cell lines displayed similar responses to THD, with IC_{50} of 20.91 and 18.54 μM, respectively. For DDP, cell survival percentages in A549/DDP cells were higher than those in A549 cells, with IC_{50} of 45.44 and 116.92 μM, respectively, confirming the resistance property of A549/DDP. Therefore, 20 μM THD and 40 μM DDP were chosen for the combination therapy.

The combination regimen (THD+DDP) led to the lowest cell survival percentage (A549: \(p < 0.001\); A549/DDP: \(p < 0.001\)) (Figures 1(c)–1(e)). CI were 1.09 (1.07–1.12) in A549 cells (i.e., addition) and 1.18 (1.10–1.30) in A549/DDP cells (i.e., synergism). These data indicated that THD synergized DDP against resistant cells.

3.2. THD Enhanced Apoptosis Due to DDP. DDP led to a lower apoptosis percentage in A549/DDP cells compared with A549 cells (23.0 ± 1.3% vs. 31.1 ± 2.1%, \(p = 0.040\)). The apoptosis percentage in the combination regimen was higher than that after receiving THD or DDP (A549: \(p < 0.001\); A549/DDP: \(p < 0.001\)) (Figure 2). Late apoptosis had a higher weight. These data manifested that THD can enhance DDP-induced apoptosis.

3.3. THD Decreased GSH. The levels of total and reduced GSH in A549/DDP cells were higher than those in A549 cells (\(p < 0.001\), \(p < 0.001\)). THD or the combination regimen decreased the levels of total and reduced GSH (A549: THD \(p = 0.007\), combination \(p < 0.001\); A549/DDP: THD \(p < 0.001\), combination \(p < 0.001\)), but increases were noted after DDP treatment (A549: \(p < 0.001\); A549/DDP: \(p < 0.001\)) (Figure 3(a)). A higher ROS level was detected after THD treatment, with the highest level in cells receiving the combination regimen (A549: \(p < 0.001\); A549/DDP: \(p = 0.001\)) (Figure 3(d)). These data indicated that THD can decrease the intracellular level of GSH.

3.4. THD Enhanced DDP-Induced DNA Damage. Alkaline and neutral assays demonstrated that THD, DDP, and the combination induced comet formation, and the combination regimen resulted in the highest comet percentage (A549: \(p < 0.001\) for each; A549/DDP: \(p < 0.001\) for each) (Figure 4). After DDP treatment, both the alkaline- or
neutral-comet percentage in A549/DDP cells were lower than those in A549 cells ($p < 0.001$; $p < 0.001$) (Figure 4).

BRCA2 and RAD51 were key molecules for DSB repair, and ERCC1 was the critical protein in SSB repair [18]. Western blot indicated that the level of BRCA2, RAD51, and ERCC1 was decreased after treatment with THD or the combination of THD and DDP but was increased after DDP treatment (A549: BRCA2 $p = 0.001$, RAD51 $p = 0.078$, ERCC1 $p = 0.001$; A549/DDP: BRCA2 $p = 0.007$, RAD51 $p < 0.001$, ERCC1 $p < 0.001$) (Figure 5). These data demonstrated that THD enhanced DDP-induced DNA damage and can decrease the DNA repair capacity in resistant cells.

4. Discussion

DNA was the preferred target of DDP. DDP frequently attacked guanine and adenine to induce intra- and interstand crosslinks, causing SSB and DSB [19, 20]. Most SSB can be repairable and partial SSB would evolve into DSB; unreparable DSB triggered apoptosis to deactivate cells [21]. Resistant cells had a higher capacity of DNA repair, thereby protecting cells from DNA damage [21]. These were consistent with the present data that the cell survival was higher and apoptosis and comet percentages were lower in A549/DDP cells than those in A549 cells. Therefore, chemosensitization due to THD was explored from the perspective of DNA damage in the present study.

Data on cytotoxicity and apoptosis accorded with the previous findings, verifying the sensitization effect of THD, i.e., data on DNA damage in this study were valuable [10]. Comet percentages in the combination group were higher than those in the DDP group, indicating that THD enhanced DNA damage induced by DDP. An exacerbation of DNA damage caused more cells undergo apoptosis. Here, the ratio of neutral- to alkaline-comet percentages was $>76\%$ in the combination therapy, i.e., most damage was DSB. In resistant ovarian cancer cells COC1/DDP, the ratio was $<40\%$ when using cyclosporin/ultrasound to sensitize DDP, or exposure to electric pulses [20]. These data indicated that the feature of DNA damage depended on cell type and the therapeutic means. Increasing the proportion of DSB favored apoptosis. Thus, THD modulated DNA insults, promoted apoptosis, and eventually synergized DDP.

DSB was repaired via homologous recombination (HR), where BRCA2 and RAD51 were essential molecules [22, 23]. ERCC1 was the key protein for nucleotide excision repair (NER) that repaired SSB [24, 25]. Lung cancer patients with a high expression level of those molecules in cancer tissues had poor therapeutic responses and shorter survival time [24]. The present data showed that THD decreased the level of these 3 proteins, indicating that both SSB and DSB repairs were suppressed. The persistence of SSB and DSB accumulated errors, resulting in cell death.
Upregulation of these proteins was noted after DDP treatment, which was consistent with previous reports and was inductive expression [26]. DNA damage attributable to DDP activated the adaptive responses to protect cells. Consequently, the repair capacity can be actually decreased only when the downregulation effect surpassed the upregulation effect. In this study, the levels in the combination group did not exceed those in the THD group. This played a part in the highest comet percentages observed in the combination group.

Intracellular processes of DDP included activation (i.e., forming hydrated platinum) and inactivation. DDP was inactivated when binding with GSH and metallothioneins, and the conjugate was pumped out by GS-X [27]. A high intracellular level of GSH led to DDP resistance, and decreasing GSH improved the cells’ sensitivity to DDP [28]. This verdict accorded with the present data that a higher GSH level was detected in A549/DDP cells. THD decreased the GSH level, thereby increasing the intracellular amount of active platinum. That THD reduced GSH via lowering the yield or accelerating the degradation should be elucidated. ROS was involved in the action of DDP, and a decrease in ROS related to resistance [29, 30]. ROS mediated cytotoxicity via lipid peroxidation. Here, the combination led to the highest ROS level, implying that THD can facilitate the ROS generation attributable to DDP. Additionally, GSH was an antioxidant that can scavenge ROS. THD decreased the GSH level, favoring intracellular accumulation of ROS.

Noticably, for cell death and apoptosis, A549 and A549/DDP cells displayed similar responses to THD; THD also enhanced the action of DDP on A549 cells from the perspective of cell apoptosis and DNA damage. This can be an advantage, i.e., determining the DDP sensitivity prior to treatments was unnecessary. The present study was an in vitro trial, and therefore the aforementioned verdicts should be tested in vivo.

Figure 2: Apoptosis after treatments with THD and/or DDP in A549 (a, b) and A549/DDP (a, c) cells. The combination regimen caused the highest apoptosis percentage. Data were mean ± standard deviation for 3 independent experiments. a vs. group ctrl, \( p < 0.05 \); b vs. group THD, \( p < 0.05 \); c vs. group DDP, \( p < 0.05 \).
Figure 3: Levels of GSH and ROS. Total and reduced GSH were decreased after receiving THD or the combination regimen (a, b). ROS level (d): a higher level was detected after treatments with THD or the combination regimen. Data were mean ± standard deviation for 3 independent experiments. a vs. group ctrl, $p < 0.05$; b vs. group THD, $p < 0.05$; c vs. group DDP, $p < 0.05$. ∗$p < 0.05$.

Figure 4: Continued.
Figure 4: DNA damage after exposure to THD and/or DDP. Representative comet images (a, b). Comet percentages in the alkaline (c) or neutral (d) assay: the highest value was noted after receiving the combination regimen. Data were mean ± standard deviation for 3 independent experiments. a vs. group ctrl, \( p < 0.05 \); b vs. group THD, \( p < 0.05 \); c vs. group DDP, \( p < 0.05 \), * \( p < 0.05 \).

Figure 5: Continued.
In summary, THD reduced the GSH level to increase the intracellular amount of active platinum; THD downregulated the levels of ERCC1, BRCA2, and RAD51 proteins, thereby decreasing the DNA repair capacity. These effects enhanced DDP-induced DNA damage, promoted/exacerbated DSB, and eventually triggered apoptosis to deactivate resistant lung cancer cells (Figure 6).

Figure 5: DNA-repair related proteins BRCA2, RAD51, and ERCC1 validated by western blot in A549 (a, b) and A549/DDP (a, c) cells. Levels of BRCA2, RAD51, and ERCC1 were decreased after receiving THD or the combination regimen but were increased after DDP treatment. Data were mean ± standard deviation for 3 independent experiments. a vs. group ctrl, \( p < 0.05 \); b vs. group THD, \( p < 0.05 \); c vs. group DDP, \( p < 0.05 \).

Figure 6: Illustration of mechanisms. THD enhanced DDP via decreasing detoxification and DNA repair.
Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Acknowledgments
This work was supported by the Kuanren Talents Program of the second affiliated hospital of Chongqing Medical University (2020).

References
[1] S. Dasari and P. Bernard Tchounwou, “Cisplatin in cancer therapy: molecular mechanisms of action,” European Journal of Pharmacology, vol. 740, pp. 364–378, 2014.
[2] J. Chen, C. Solomides, H. Parekh, F. Simpkins, and H. Simpkins, “Cisplatin resistance in human cervical, ovarian and lung cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 75, no. 6, pp. 1217–1227, 2015.
[3] Y. Zhang, J. Li, and T. Yu, “Pharmacokinetic profiles of cancer sonochemotherapy,” Expert Opinion on Drug Delivery, vol. 14, no. 6, pp. 745–753, 2017.
[4] N. Abu, K. W. Hon, S. Jayaraman, and R. Jamal, “Long non-coding RNAs as biotargets in cisplatin-based drug resistance,” Future Oncology, vol. 14, no. 29, pp. 3085–3095, 2018.
[5] J. E. Haber, “DNA repair: the search for homology,” BioEssays, vol. 40, no. 5, Article ID e1700029, 2018.
[6] T. Makovec, “Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy,” Radiology and Oncology, vol. 53, no. 2, pp. 148–158, 2019.
[7] B. Wan, L. Dai, L. Wang et al., “Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells,” Endocrine-Related Cancer, vol. 25, no. 1, pp. 69–82, 2018.
[8] M. Mao, T. Yu, J. Hu, and L. Hu, “Dopamine D2 receptor blocker thioridazine induces cell death in human uterine cervical carcinoma cell line SiHa,” Journal of Obstetrics and Gynaecology Research, vol. 41, no. 8, pp. 1240–1245, 2015.
[9] X. Jiang, Z. Chen, G. Shen et al., “Psychotropic agent thioridazine elicits potent in vitro and in vivo anti-melanoma effects,” BioMedicine & Pharmacotherapy, vol. 97, pp. 833–837, 2018.
[10] G. Qian, L. Dai, and T. Yu, “Thioridazine sensitizes cisplatin against chemoresistant human lung and ovary cancer cells,” DNA and Cell Biology, vol. 38, no. 7, pp. 718–724, 2019.
[11] C.-W. Chu, H.-J. Ko, C.-H. Chou et al., “Thioridazine enhances P62-mediated autophagy and apoptosis through wt1/β-catenin signaling pathway in glioma cells,” International Journal of Molecular Sciences, vol. 20, no. 3, p. 473, 2019.
[12] G. Spengler, A. Csonka, J. Molnár, and L. Amaral, “The anticancer activity of the old neuroleptic phenothiazine-type drug thioridazine,” Anticancer Research, vol. 36, no. 11, pp. 5701–5706, 2016.
[13] T. Yu, L. Luo, and L. Wang, “Ultrasound as a cancer chemotherapy sensitizer: the gap between laboratory and bedside,” Expert Opinion on Drug Delivery, vol. 13, no. 1, pp. 37–47, 2016.
[14] Q. Liu, X. Zhong, Y. Zhang, X. Li, G. Qian, and T. Yu, “Ultrasound enhances ZD2767P-carboxypeptidase G2 against chemoresistant ovarian cancer cells by altering the intracellular pharmacokinetics of ZD2767D,” Molecular Pharmacology, vol. 17, no. 6, pp. 1922–1932, 2020.
[15] F. Wang, P. Zhang, Y. Ma et al., “NIRF is frequently upregulated in colorectal cancer and its oncogenicity can be suppressed by let-7a microRNA,” Cancer Letters, vol. 314, no. 2, pp. 223–231, 2012.
[16] J. Zou, Y. Zhang, J. Sun et al., “Doxycycline enhances reactive oxygen species-mediated apoptosis and autophagy in human osteosarcoma cells,” Cellular Physiology and Biochemistry, vol. 42, no. 5, pp. 1812–1821, 2017.
[17] H. He, H. Huang, and T. Yu, “Detection of DNA damage in sonochemotherapy against cisplatin-resistant human ovarian cancer cells using the modified comet assay,” International Journal of Radiation Biology, vol. 90, no. 10, pp. 897–902, 2014.
[18] J. -Y. Park, S. Kim, H. Y. Sohn, Y. H. Koh, and C. Jo, “TFEB activates Nrf2 by repressing its E3 ubiquitin ligase DCAF11 and promoting phosphorylation of p62,” Scientific Reports, vol. 9, no. 1, Article ID 14354, 2019.
[19] S. Ghosh, “Cisplatin: the first metal based anticancer drug,” Bioorganic Chemistry, vol. 88, Article ID 102925, 2019.
[20] G. Qian and T. Yu, “Nanosecond electric pulses induce early and late phases of DNA damage and cell death in cisplatin-resistant human ovarian cancer cells,” BioMed Research International, vol. 2018, Article ID 4504895, 7 pages, 2018.
[21] L. P. Martin, T. C. Hamilton, and R. J. Schilder, “Platinum resistance: the role of DNA repair pathways,” Clinical Cancer Research, vol. 14, no. 5, pp. 1291–1295, 2008.
[22] A. M. Kolinjivadi, V. Sannino, A. de Antoni, H. Técher, G. Baldi, and V. Costanzo, “Moonlighting at replication forks—a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51,” FEBS Letters, vol. 591, no. 8, pp. 1083–1100, 2017.
[23] Y. Sun, T. J. McCorvie, L. A. Yates, and X. Zhang, “Structural basis of homologous recombination,” Cellular and Molecular Life Sciences, vol. 77, no. 1, pp. 3–18, 2020.
[24] G. Hamilton and B. Rath, “Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1,” Expert Opinion on Drug Metabolism and Toxicology, vol. 14, no. 1, pp. 17–24, 2017.
[25] E. Fadda, “Conformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motif,” Biophysical Journal, vol. 104, no. 11, pp. 2503–2511, 2013.
[26] W. P. Roos, A. D. Komas, and B. Kaina, “DNA damage and the balance between survival and death in cancer biology,” Nature Reviews Cancer, vol. 16, no. 1, pp. 20–33, 2016.
[27] S. Rottenberg, C. Dísler, and P. Pereg, “The rediscovery of platinum-based cancer therapy,” Nature Reviews Cancer, vol. 21, no. 1, pp. 37–50, 2021.
[28] H.-X. Zhang, Y. Chen, R. Xu, and Q.-Y. He, “Nrf2 mediates the resistance of human A549 and HepG2 cancer cells to boningmycin, a new antitumor antibiotic, in vitro through regulation of glutathione levels,” Acta Pharmacologica Sinica, vol. 39, no. 10, pp. 1661–1669, 2018.
[29] P. B. Tchounwou, S. Dasari, F. K. Noubissi, P. Ray, and S. Kumar, “Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy,” Journal of Experimental Pharmacology, vol. 13, pp. 303–328, 2021.
[30] P. Lv, S. Man, L. Xie, L. Má, and W. Gao, “Pathogenesis and therapeutic strategy in platinum resistance lung cancer,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, vol. 1876, no. 1, Article ID 188577, 2021.